NCT03732352 - 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 28, 2018

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2024

Conditions

EGFR Gene AmplificationEGFR Gene MutationGlioblastomaRecurrent GlioblastomaSupratentorial GlioblastomaTP53 Wt Allele

Interventions

OTHER

Fludeoxyglucose F-18

Given IV

DRUG

Osimertinib

Given PO

PROCEDURE

Positron Emission Tomography

Undergo fludeoxyglucose F-18 PET scan

Trial Locations (1)

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles